ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
RUNX1-Mediated Hypoxic Signaling Impairs Myogenesis and Promotes Fibrosis in Myopathies.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Compromised myogenic repair with enhanced fibrosis is common in myopathies, including Wooden Breast (WB) myopathy in broilers, but the underlying mechanism of their co-occurrence remains elusive. Using WB myopathy as a model, we investigated the common pathological origins of these co-occurring features. Our single-nucleus RNA sequencing results showed enhanced oxidative stress and profibrotic remodeling of myofibers, increased proliferation but decreased differentiation of satellite cells (SCs), and aggravated differentiation of fibroblasts (FBs) in WB samples. Differential gene expression and pseudotime trajectory analysis further identified RUNX1 as a key regulator for both SCs and FBs, which was further supported by gene functional studies in respective cell culture models. Moreover, reduced blood flow and oxygen supply may indicate a hypoxic state in WB muscle, which was associated with enhanced RUNX1 expression. Consistently, coordinately enhanced HIF1A and RUNX1 expressions were found in differentiated FBs of human muscles and in muscles with diseases. Collectively, our study found that hypoxia-associated upregulation of RUNX1 disrupted the myogenic progression of SCs and exacerbated fibrotic differentiation of FBs, contributing to pathological degeneration in myopathies. Targeting RUNX1 may therefore represent a potential therapeutic strategy for prevention and treatment, which warrants future in vivo investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.